StoxAjanta Pharmaceuticals vs Wockhardt: share price & financials comparison
NSE: AJANTPHARM vs WOCKPHARMA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Ajanta Pharmaceuticals vs Wockhardt at a glance
Ajanta Pharmaceuticals (AJANTPHARM) has a market capitalisation of ₹41,165 Cr, against ₹32,841 Cr for Wockhardt (WOCKPHARMA). Over the past year Wockhardt has returned +48.5%, compared with +25.8% for Ajanta Pharmaceuticals. On valuation, Ajanta Pharmaceuticals trades at a lower P/E of 32.7 versus 80.1. Ajanta Pharmaceuticals earns a higher return on equity (25.9% vs 7.9%). Ajanta Pharmaceuticals comes out ahead on size, profitability, growth and financial health. Wockhardt comes out ahead on momentum and technicals. Across the scored metrics below, Ajanta Pharmaceuticals leads on 11 and Wockhardt on 6. On StoxGud's 10-point checklist, Ajanta Pharmaceuticals scores 9/10 and Wockhardt scores 6/10.
| Metric | Ajanta Pharmaceuticals | Wockhardt |
|---|---|---|
| Size | ||
| Market cap | ₹41,165 Cr | ₹32,841 Cr |
| Revenue (latest FY) | ₹5,453 Cr | ₹3,373 Cr |
| Net profit (latest FY) | ₹1,056 Cr | ₹213 Cr |
| Valuation | ||
| P/E | 32.7 | 80.1 |
| P/B | 8.47 | 6.37 |
| Dividend yield | 0.85% | — |
| Profitability | ||
| Return on equity | 25.9% | 7.9% |
| Net profit margin | 20.2% | 10.9% |
| Operating margin | 27.1% | 20.4% |
| Growth | ||
| Revenue growth (YoY) | +32.5% | +23.9% |
| Net profit growth (YoY) | +49.2% | +1.3% |
| Revenue CAGR (multi-year) | +13.5% | +4.5% |
| Financial health | ||
| Debt to equity | 0.02 | 0.42 |
| Momentum | ||
| 1-month return | -1.3% | +2.2% |
| 1-year return | +25.8% | +48.5% |
| 3-year CAGR | +20.7% | +92.3% |
| 5-year CAGR | +17.8% | +36.5% |
| 10-year CAGR | +11.2% | +11.2% |
| Distance from 52W high | -11.7% | -13.0% |
| Technicals | ||
| RSI (14) | 50 | 74 |
| Price vs 200-day avg | +2.9% | +17.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Ajanta Pharmaceuticals | Wockhardt |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Ajanta Pharmaceuticals or Wockhardt?
Ajanta Pharmaceuticals has a market cap of ₹41,165 Cr and Wockhardt has a market cap of ₹32,841 Cr as of 13 Nov 2026.
Which has a lower P/E, Ajanta Pharmaceuticals or Wockhardt?
Ajanta Pharmaceuticals has the lower P/E: Ajanta Pharmaceuticals trades at 32.7 and Wockhardt at 80.1.
Which gave better returns in the last year, Ajanta Pharmaceuticals or Wockhardt?
Wockhardt did better: Ajanta Pharmaceuticals returned +25.8% and Wockhardt returned +48.5% over one year.
What is the difference between Ajanta Pharmaceuticals and Wockhardt?
Both are NSE-listed companies in Healthcare. Ajanta Pharmaceuticals is about 1.3 times the size of Wockhardt by market cap. In the latest financial year Ajanta Pharmaceuticals reported revenue of ₹5,453 Cr and Wockhardt ₹3,373 Cr. Operating margin is 27.1% for Ajanta Pharmaceuticals and 20.4% for Wockhardt. Debt to equity is 0.02 for Ajanta Pharmaceuticals and 0.42 for Wockhardt.
Which is better, Ajanta Pharmaceuticals or Wockhardt?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Ajanta Pharmaceuticals leads on 11 and Wockhardt on 6. Ajanta Pharmaceuticals is ahead on size, profitability, growth and financial health. Wockhardt is ahead on momentum and technicals. On StoxGud's rules-based checklist Ajanta Pharmaceuticals scores 9/10 and Wockhardt scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.